I'll research DHR before writing the preview. Let me start by gathering recent filings, transcripts, and news.Let me read the most recent earnings call and release (2026Q1) for guidance heading into Q2.I have strong context from Q1. Now let me get stock performance and recent news/analyst expectations heading into the print.Let me quickly pull the year-ago Q2 (2025Q2) release for clean comparison figures.I have everything I need. Here's the earnings preview.
Danaher heads into Q2 as a "show-me" story on a second-half re-acceleration it has promised but not yet delivered, with the key swing factor being whether the early bioprocessing equipment recovery is real and durable — set against a still-muted Life Sciences backdrop, China diagnostics pricing headwinds, and a pending Masimo acquisition that reshapes the capital-deployment narrative.
For Q2, the Street models organic revenue growth of approximately 2% with EPS of $1.84 and adjusted operating margins of 26.6%. That EPS estimate compares against year-ago Q2 2025 adjusted EPS, so consensus implies only low-single-digit earnings growth this quarter — a soft-looking bar by design, given tough comps and seasonal respiratory drag.
Management's own framing from the Q1 call is consistent with the Street: - In the second quarter, we expect core revenue to be up low single digits, and we expect the second quarter adjusted operating profit margin of approximately 26.5%. - By segment for Q2, guidance calls for Biotechnology up mid-single digits, Life Sciences up slightly, Diagnostics roughly flat, and total company up low-single digits.
Year-ago comparison base (Q2 2025): Net earnings were $555 million, or $0.77 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.80. Revenues increased 3.5% year-over-year to $5.9 billion and non-GAAP core revenue increased 1.5% year-over-year. So consensus of ~$1.84 / ~2% core represents modest acceleration off a low base.
Coming out of Q1, Danaher held its top-line range and nudged up EPS: For the full year 2026, there is no change to our expectation of core revenue growth in the 3% to 6% range. Given our strong Q1 performance, we're raising our full year adjusted diluted net EPS guidance to a range of $8.35 to $8.55 versus our previous range of $8.35 to $8.50.
Key FY2026 modeling assumptions embedded in the guide: - Cepheid respiratory revenue of ~$1.6–1.7B, FX +0.5% to sales, effective tax rate ~17%, net interest expense ~$140M, corporate expense ~$360M, and ~714M average diluted shares. - Segment full-year: Biotechnology ~+6%, Life Sciences up slightly, Diagnostics low-single digit.
What to watch: Danaher has anchored to the low end of the core-growth range for planning purposes. A Q1-style EPS beat could prompt another EPS raise, but the top-line range is likely to hold. The credibility of the second-half ramp is the crux — management insists the math works without any end-market improvement: the headwinds that we've talked about, China diagnostics, respiratory, some of the comps in Life Sciences, they're collectively about a 300 basis point, maybe a little bit higher impact in the first half of the year. These essentially go away by the end of the year and why we believe we'll exit Q4 in that mid-single-digit range.
This is the single most important data point in the print. Consumables strength has been steady, but the debate is on equipment. In Q1: High single-digit growth in consumables was driven by robust demand for commercialized therapies globally with notable strength in China. Equipment declined modestly in Q1, but we were encouraged to see orders growth of more than 30%, marking the first quarter of year-over-year equipment order growth in nearly 2 years.
Management frames this as the early innings of a multiyear capacity cycle, driven by underinvestment plus reshoring. We're encouraged by improved trends in bioprocessing equipment and believe we're in the early stages of a multiyear investment cycle. A second consecutive quarter of strong equipment orders would substantially de-risk both the 2H ramp and 2027 setup; a stall would raise questions about lumpiness and customer readiness (a caveat management flagged).
Diagnostics core fell 4% in Q1, dragged by China. we feel good about our assumptions around the $75 million to $100 million headwind there in China. Encouragingly, volume growth in China was slightly better than our expectations, an encouraging indicator for future demand and growth as we move past the most significant year-over-year impacts from current policy headwinds. Watch for confirmation that VBP/reimbursement pressure remains on-script and that ex-China diagnostics keeps posting mid-single-digit growth.
Life Sciences was better than feared in Q1 (+0.5% core). The read-through to watch: order book momentum, Aldevron and Abcam (consumables), China instrument reinvestment, and the still-muted-but-stable US academic/government picture. While demand at academic research customers remain muted in the quarter, we saw early signs of momentum building in our order book.
Q1 was hurt by a light respiratory season (respiratory down ~25% y/y), offset by a strong core menu. The full-year assumes ~$1.6–1.7B of respiratory revenue, and management needs a normal-to-above-normal Q4 season (back toward a ~$1.8B endemic run-rate) to hit the high end. Q2 is seasonally the low quarter for respiratory, so the focus will be on non-respiratory molecular momentum (sexual health, HAI, the new GI panel) rather than the respiratory number itself.
The pending Masimo deal is a key narrative shift. Management positions it as a classic Danaher acquisition into acute-care diagnostics adjacent to Radiometer. We expect Masimo to be accretive to adjusted diluted net earnings per common share in the first full year post acquisition and to deliver high single-digit return on invested capital by the fifth full year of our ownership. Synergy targets: $125 million of cost synergies realized by year 5... and about $50 million of revenue synergies.
Watch for: updated deal timing / regulatory progress (expected to close "later this year"), financing details, and the balance-sheet impact — post close of Masimo, we'll go to about 2.5x net debt EBITDA, with management stressing continued M&A capacity given $5B+ annual free cash flow. Note current guidance excludes incremental interest expense from the Masimo financing, so a close could shift the interest-expense assumption.
DHR closed around $201 on July 20, well off its January 2026 high near $242 and down roughly 13% year-to-date, though it has recovered from a May 2026 low near $162. The stock has been a persistent underperformer versus large-cap peers, so sentiment is cautious/skeptical — which raises the payoff to any credible sign of the promised 2H acceleration. Recent sentiment has firmed: Sentiment around lab equipment stocks has improved recently due to positive fundamental data points from Agilent and ICON PLC earnings and M&A activity including Merck KGaA's acquisition of Bio-Techne. (A minor note: a director filed a routine intent-to-sell ~$658k of stock on July 14 — not material.)
The low ~2% consensus and beaten-down stock mean the bar for the quarter itself is modest; the report will likely be judged less on Q2 print precision and more on whether management can convincingly reaffirm the exit-Q4 mid-single-digit trajectory and the bioprocessing recovery thesis into 2027.
Note: Danaher labels this the "2026Q2" (June-ending) quarter; all figures are non-GAAP core/adjusted unless stated.